Literature DB >> 32868409

Overlapping Peptides Elicit Distinct CD8+ T Cell Responses following Influenza A Virus Infection.

Lisa M Assmus1,2,3, Jing Guan1, Ting Wu1, Carine Farenc1, Xavier Y X Sng1, Pirooz Zareie1, Angela Nguyen1, Andrea T Nguyen1, David C Tscharke4, Paul G Thomas5, Jamie Rossjohn1,6,7, Stephanie Gras1, Nathan P Croft8, Anthony W Purcell8, Nicole L La Gruta8.   

Abstract

The presentation of pathogen-derived peptides on MHC class I molecules is essential for the initiation of adaptive CD8+ T cell immunity, which in turn is critical for effective control of many significant human infections. The identification of immunogenic pathogen-derived epitopes and a detailed understanding of how they are recognized by TCRs is essential for the design of effective T cell-based vaccines. In this study, we have characterized the T cell recognition and immune responses in mice to two naturally presented influenza A virus-derived peptides previously identified from virally infected cells via mass spectrometry. These neuraminidase-derived peptides, NA181-190 (SGPDNGAVAV) and NA181-191 (SGPDNGAVAVL), are completely overlapping with the exception of a 1 aa extension at the C terminus of the longer peptide. This minor peptidic difference results in the induction of two completely independent and non-cross-reactive T cell populations that show distinct functional characteristics after influenza A virus infection of B6 mice. We show that the unique TCR reactivity to the overlapping peptides is present in the naive repertoire prior to immune expansion in B6 mice. Moreover, we provide a structural explanation underlying the distinct CD8+ T cell reactivities, which reinforces the concept that peptide length is a key determinant of Ag specificity in CD8+ T cell responses.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32868409      PMCID: PMC7511415          DOI: 10.4049/jimmunol.2000689

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  A structure-based approach for prediction of MHC-binding peptides.

Authors:  Yael Altuvia; Hanah Margalit
Journal:  Methods       Date:  2004-12       Impact factor: 3.608

Review 2.  Sizing up the key determinants of the CD8(+) T cell response.

Authors:  David C Tscharke; Nathan P Croft; Peter C Doherty; Nicole L La Gruta
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

3.  Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT.

Authors:  E Blanc; P Roversi; C Vonrhein; C Flensburg; S M Lea; G Bricogne
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

4.  HLA peptide length preferences control CD8+ T cell responses.

Authors:  Melissa J Rist; Alex Theodossis; Nathan P Croft; Michelle A Neller; Andrew Welland; Zhenjun Chen; Lucy C Sullivan; Jacqueline M Burrows; John J Miles; Rebekah M Brennan; Stephanie Gras; Rajiv Khanna; Andrew G Brooks; James McCluskey; Anthony W Purcell; Jamie Rossjohn; Scott R Burrows
Journal:  J Immunol       Date:  2013-06-07       Impact factor: 5.422

5.  Acute emergence and reversion of influenza A virus quasispecies within CD8+ T cell antigenic peptides.

Authors:  Sophie A Valkenburg; Sergio Quiñones-Parra; Stephanie Gras; Naomi Komadina; Jodie McVernon; Zhongfang Wang; Hanim Halim; Pina Iannello; Catherine Cole; Karen Laurie; Anne Kelso; Jamie Rossjohn; Peter C Doherty; Stephen J Turner; Katherine Kedzierska
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

6.  Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity.

Authors:  Nicole L La Gruta; Stephen J Turner; Peter C Doherty
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

7.  Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold.

Authors:  Sophie A Valkenburg; Stephanie Gras; Carole Guillonneau; Nicole L La Gruta; Paul G Thomas; Anthony W Purcell; Jamie Rossjohn; Peter C Doherty; Stephen J Turner; Katherine Kedzierska
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

8.  ERAP1 enzyme-mediated trimming and structural analyses of MHC I-bound precursor peptides yield novel insights into antigen processing and presentation.

Authors:  Lenong Li; Mansoor Batliwala; Marlene Bouvier
Journal:  J Biol Chem       Date:  2019-10-10       Impact factor: 5.157

9.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis.

Authors:  Xavier Brochet; Marie-Paule Lefranc; Véronique Giudicelli
Journal:  Nucleic Acids Res       Date:  2008-05-24       Impact factor: 16.971

10.  T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability.

Authors:  Timothy P Riley; Lance M Hellman; Marvin H Gee; Juan L Mendoza; Jesus A Alonso; Kendra C Foley; Michael I Nishimura; Craig W Vander Kooi; K Christopher Garcia; Brian M Baker
Journal:  Nat Chem Biol       Date:  2018-09-17       Impact factor: 15.040

View more
  3 in total

1.  Breast cancer is marked by specific, Public T-cell receptor CDR3 regions shared by mice and humans.

Authors:  Miri Gordin; Hagit Philip; Alona Zilberberg; Moriah Gidoni; Raanan Margalit; Christopher Clouser; Kristofor Adams; Francois Vigneault; Irun R Cohen; Gur Yaari; Sol Efroni
Journal:  PLoS Comput Biol       Date:  2021-01-19       Impact factor: 4.475

2.  Proteasome-Generated cis-Spliced Peptides and Their Potential Role in CD8+ T Cell Tolerance.

Authors:  Artem Mansurkhodzhaev; Camila R R Barbosa; Michele Mishto; Juliane Liepe
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

3.  Potential Mimicry of Viral and Pancreatic β Cell Antigens Through Non-Spliced and cis-Spliced Zwitter Epitope Candidates in Type 1 Diabetes.

Authors:  Michele Mishto; Artem Mansurkhodzhaev; Teresa Rodriguez-Calvo; Juliane Liepe
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.